Enhancing clinical evidence by proactively building quality into clinical trials

Clinical Trials

Volumn 13, Issue 4, 2016, Pages 439-444

  Meeker O'Connell, Ann ^a,g   Glessner, Coleen ^b   Behm, Mark ^c   Mulinde, Jean ^d   Roach, Nancy ^e   Sweeney, Fergus ^f   Tenaerts, Pamela ^g   Landray, Martin J ^h  

^a JOHNSON AND JOHNSON   (United States)

^b Alexion Corporation   (United States)

^c ASTRAZENECA   (United Kingdom)

^d CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^e Patient Advocacy   (United States)

^f EUROPEAN MEDICINES AGENCY   (United Kingdom)

^g DUKE UNIVERSITY   (United States)

^h UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

clinical trial; good clinical practice; quality assurance; quality by design

Indexed keywords

ANALYTICAL ERROR; ARTICLE; CLINICAL EVALUATION; CLINICAL STUDY; CLINICAL TRIALS TRANSFORMATION INITIATIVE; DECISION MAKING; FEASIBILITY STUDY; HEALTH CARE DELIVERY; HUMAN; INTERVIEW; ONLINE SYSTEM; PATIENT SAFETY; PLANNING; PRIORITY JOURNAL; PROACTIVELY BUILDING QUALITY; PROSPECTIVE STUDY; QUALITATIVE ANALYSIS; QUALITY BY DESIGN; RELIABILITY; WORKSHOP; CLINICAL TRIAL (TOPIC); MEDICAL RESEARCH; METHODOLOGY; QUALITATIVE RESEARCH; REPRODUCIBILITY; STANDARDS; STATISTICAL ANALYSIS; TOTAL QUALITY MANAGEMENT;

BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; DATA INTERPRETATION, STATISTICAL; DECISION MAKING; HUMANS; PATIENT SAFETY; QUALITATIVE RESEARCH; QUALITY IMPROVEMENT; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN;

EID: 84978933473     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1177/1740774516643491     Document Type: Article

References (21)

1. Collins R, MacMahon S,. Reliable assessment of the effects of treatment on mortality and major morbidity, I: clinical trials. Lancet 2001; 357: 373-380.
2. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989; 321: 406-412.
3. Roberts I, Yates D, Sandercock P, et al. Effect of intravenous corticosteroids on death within 14 days in 10,008 adults with clinically significant head injury (MRC CRASH trial): randomised placebo-controlled trial. Lancet 2004; 364: 1321-1328.
4. Landray MJ, Haynes R, Hopewell JC, et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med 2014; 371: 203-212.
5. President's Council of Advisors on Science and Technology. Report to the President on propelling innovation in drug discovery, development, and evaluation, https://www.whitehouse.gov/sites/default/files/microsites/ostp/pcast-fda-final.pdf (2012,. accessed 1 October 2014).
6. DiMasi JA,. Cost of developing a new drug, http://csdd.tufts.edu/files/uploads/Tufts-CSDD-briefing-on-RD-cost-study-Nov-18,-2014.pdf (2014,. accessed 1 June 2015).
7. Eapen ZJ, Lauer MS, Temple RJ,. The imperative of overcoming barriers to the conduct of large, simple trials. JAMA 2014; 311: 1397-1398.
8. Eisenstein EL, Collins R, Cracknell BS, et al. Sensible approaches for reducing clinical trial costs. Clin Trials 2008; 5: 75-84.
9. Morrison BW, Cochran CJ, White JG, et al. Monitoring the quality of conduct of clinical trials: a survey of current practices. Clin Trials 2011; 8: 342-349.
10. Baigent C, Harrell FE, Buyse M, et al. Ensuring trial validity by data quality assurance and diversification of monitoring methods. Clin Trials 2008; 5: 49-55.
11. Landray MJ, Grandinetti C, Kramer JM, et al. Clinical trials: rethinking how we ensure quality. Drug Info J 2012; 46: 657-660.
12. Clinical Trials Transformation Initiative Quality by Design Project. CTTI Recommendations: Quality by Design, http://www.ctti-clinicaltrials.org/files/QbD-toolkit/CTTI%20Quality%20by%20Design%20Recommendations-FINAL-1JUN15.pdf (2015,. accessed 15 June 2015).
13. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, Center for Devices and Radiological Health, Office of Good Clinical Practice, and Office of Regulatory Affairs. Guidance for industry: oversight of clinical investigations-a risk-based approach to monitoring, http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM269919.pdf (2013,. accessed 1 October 2014).
14. European Medicines Agency. Reflection paper on risk based quality management in clinical trials, http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2011/08/WC500110059.pdf (2011,. accessed 1 October 2014).
15. Medical Research Council/Department of Health/Medicines and Healthcare Products Regulatory Agency Joint Project. Risk-adapted approaches to the management of clinical trials of investigational medicinal products, http://webarchive.nationalarchives.gov.uk/20141205150130/http://www.mhra.gov.uk/home/groups/l-ctu/documents/websiteresources/con111784.pdf (2011,. accessed 1 October 2014).
16. Clinical Trials Transformation Initiative. Critical to quality factors, http://www.ctti-clinicaltrials.org/files/QbD-toolkit/Principles%20Document-finaldraft-19MAY15.pdf (2015,. accessed 15 June 2015).
17. Sacks LV, Shamsuddin HH, Yasinskaya YI, et al. Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, 2000-2012. JAMA 2014; 311: 378-384.
18. Getz KA, Stergiopoulos S, Marlborough M, et al. Quantifying the magnitude and cost of collecting extraneous protocol data. Am J Ther 2015; 22: 117-124.
19. Clinical Trials Transformation Initiative. Quality by Design Toolkit, http://www.ctti-clinicaltrials.org/qbd (2015,. accessed 15 June 2015).
20. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use, final concept paper-addendum for ICH E6, Guideline for Good Clinical Practice, http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Efficacy/E6/E6-R2-Addendum-Step2.pdf (2015,. accessed 10 August 2015).
21. Deming WE,. Out of the crisis. Cambridge, MA: MIT Press, 1986.